PL1618195T3 - Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe - Google Patents
Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinoweInfo
- Publication number
- PL1618195T3 PL1618195T3 PL04730318T PL04730318T PL1618195T3 PL 1618195 T3 PL1618195 T3 PL 1618195T3 PL 04730318 T PL04730318 T PL 04730318T PL 04730318 T PL04730318 T PL 04730318T PL 1618195 T3 PL1618195 T3 PL 1618195T3
- Authority
- PL
- Poland
- Prior art keywords
- myc
- sense
- nucleic acids
- antisense
- pepptido
- Prior art date
Links
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 108091008800 n-Myc Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 3
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000860A ITMI20030860A1 (it) | 2003-04-29 | 2003-04-29 | Metodo per l'inibizione selettiva del gene n-myc |
| EP04730318A EP1618195B1 (en) | 2003-04-29 | 2004-04-29 | Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and sense pepptido-nucleic acids (pna) |
| PCT/IB2004/001297 WO2004096826A2 (en) | 2003-04-29 | 2004-04-29 | Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1618195T3 true PL1618195T3 (pl) | 2008-09-30 |
Family
ID=33398059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04730318T PL1618195T3 (pl) | 2003-04-29 | 2004-04-29 | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7947657B2 (pl) |
| EP (1) | EP1618195B1 (pl) |
| JP (1) | JP4719670B2 (pl) |
| AT (1) | ATE389017T1 (pl) |
| CA (1) | CA2522890C (pl) |
| DE (1) | DE602004012404T2 (pl) |
| DK (1) | DK1618195T3 (pl) |
| ES (1) | ES2303636T3 (pl) |
| IT (1) | ITMI20030860A1 (pl) |
| PL (1) | PL1618195T3 (pl) |
| PT (1) | PT1618195E (pl) |
| WO (1) | WO2004096826A2 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06012076A (es) * | 2004-04-20 | 2007-01-25 | Nastech Pharm Co | Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero. |
| US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| JP5108530B2 (ja) * | 2005-12-26 | 2012-12-26 | 独立行政法人理化学研究所 | ＡＲＩＤ３ｂを標的とした神経芽腫の治療剤 |
| US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| US11827884B2 (en) | 2017-05-15 | 2023-11-28 | University Of Florida Research Foundation, Incorporated | Core master regulators of glioblastoma stem cells |
| KR20220017919A (ko) * | 2019-06-06 | 2022-02-14 | 덴카 주식회사 | 펩티드 핵산을 기반으로 한 아쥬반트 |
-
2003
- 2003-04-29 IT IT000860A patent/ITMI20030860A1/it unknown
-
2004
- 2004-04-29 ES ES04730318T patent/ES2303636T3/es not_active Expired - Lifetime
- 2004-04-29 CA CA2522890A patent/CA2522890C/en not_active Expired - Lifetime
- 2004-04-29 JP JP2006506541A patent/JP4719670B2/ja not_active Expired - Fee Related
- 2004-04-29 PT PT04730318T patent/PT1618195E/pt unknown
- 2004-04-29 US US10/554,291 patent/US7947657B2/en active Active
- 2004-04-29 PL PL04730318T patent/PL1618195T3/pl unknown
- 2004-04-29 WO PCT/IB2004/001297 patent/WO2004096826A2/en not_active Ceased
- 2004-04-29 AT AT04730318T patent/ATE389017T1/de active
- 2004-04-29 DE DE602004012404T patent/DE602004012404T2/de not_active Expired - Lifetime
- 2004-04-29 EP EP04730318A patent/EP1618195B1/en not_active Expired - Lifetime
- 2004-04-29 DK DK04730318T patent/DK1618195T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004012404T2 (de) | 2009-03-26 |
| ITMI20030860A1 (it) | 2004-10-30 |
| JP2006525010A (ja) | 2006-11-09 |
| WO2004096826A3 (en) | 2005-05-26 |
| US20070020632A1 (en) | 2007-01-25 |
| ES2303636T3 (es) | 2008-08-16 |
| DK1618195T3 (da) | 2008-07-07 |
| JP4719670B2 (ja) | 2011-07-06 |
| ATE389017T1 (de) | 2008-03-15 |
| PT1618195E (pt) | 2008-06-24 |
| CA2522890A1 (en) | 2004-11-11 |
| WO2004096826A2 (en) | 2004-11-11 |
| DE602004012404D1 (de) | 2008-04-24 |
| CA2522890C (en) | 2013-07-02 |
| EP1618195B1 (en) | 2008-03-12 |
| US7947657B2 (en) | 2011-05-24 |
| EP1618195A2 (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE334657T1 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
| WO2001048190A3 (en) | Therapeutic uses of lna-modified oligonucleotides | |
| WO2007143315A3 (en) | Compounds and methods for modulating expression of pcsk9 | |
| WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
| WO2005002643A3 (en) | Method and products for delivering biological molecules to cells using multicomponent nanostructures | |
| EP1248794A4 (en) | ANTISENS MODULATION OF THE SMAD7 EXPRESSION | |
| DK1053313T3 (da) | Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser | |
| DE60332363D1 (de) | Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
| Sikora et al. | Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vivo | |
| EP1513859A4 (en) | KINASESUPPRESSOR OF RAS INACTIVATION FOR THE THERAPY OF RAS-ASSOCIATED TUMORGENESIS | |
| PT1618195E (pt) | Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido | |
| GB0418388D0 (en) | Cell therapy | |
| MXPA05010575A (es) | Peptacuerpo para el tratamiento del cancer. | |
| ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
| WO2001083513A3 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
| AU2180501A (en) | Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide | |
| WO2004013313A3 (en) | Antisense nucleic acids | |
| WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
| WO2007134907A3 (en) | Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system | |
| ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung | |
| EP1086116A4 (en) | COMPOSITIONS AND METHODS FOR THE PULMONATIVE TRANSPORT OF NUCLEIC ACIDS | |
| TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system | |
| EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака |